Down 40%, but I'm backing this ASX 200 stock to fly like the CSL share price

I think this business is a very healthy opportunity.

| More on:
Shot of two young scientists using a laptop in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Down around 40% since December 2021, the S&P/ASX 200 Index (ASX: XJO) stock Sonic Healthcare Ltd (ASX: SHL) is undervalued, in my view. I believe the market is underestimating Sonic's potential.

Just as international expansion has helped fellow ASX healthcare share CSL Ltd (ASX: CSL) shares (which is up 14% since 19 April), I think the Sonic share price can grow thanks to its global growth aspirations.

But there's more to like about the company than just the fact it's a global pathology business with operations in Australia, the United Kingdom, the United States, Germany and Switzerland.

Here's why I think Sonic Healthcare shares can rise in the long term.

Ongoing organic growth

A key thing I like to see from an ASX 200 stock is solid revenue growth because that's a key driver of profit growth.

In May, Sonic announced that its organic growth in the four months to 30 April 2024 was "strong" at 6%. I think that is a solid growth rate for what's a rather defensive, stable area of the healthcare market.

There are a few tailwinds that can help the company including the ageing demographics in western countries, as well as increasingly advanced technology that could help unlock new revenue streams.

Acquisitions and investments

Sonic Healthcare earned a lot of profit during the COVID-19 pandemic as it carried out millions of tests. This led to a significant amount of cash flow which the company has used to make a number of acquisitions such as SYNLAB Suisse and Dr Risch in Switzerland and PathologyWatch in the USA.

Sonic Healthcare is making significant investments in digital pathology and AI to unlock "upside opportunities".

Franklin.ai is a joint venture involving Sonic. The ASX 200 stock noted that 2024 will see validation studies and the launch of the first anatomical pathology AI product, supported by Sonic pathologists globally. Franklin.ai products will be deployed within Sonic and sold globally.

Sonic said that digital pathology and AI were set to "transform anatomical pathology through step-change gains in efficiency, quality, capacity and workflow optimisation."

Profit to improve?

The ASX 200 stock expects to report earnings before interest, tax, depreciation, and amortisation (EBITDA) of approximately $1.6 billion in FY24. The company then predicts EBITDA growth of between 6.25% and 9.4% in FY25.

I think profit growth is the best way to encourage investors to pay more for Sonic Healthcare shares.

Currently, the estimates on Commsec suggest the company's earnings per share (EPS) could rise by 32.5% between FY24 and FY26. With the ASX 200 stock trading at 20x FY26's estimated earnings, I think there is good scope for the business to deliver good capital growth over the next two or three years.

Motley Fool contributor Tristan Harrison has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Mesoblast shares dip then flip on $800,000 insider buy

The Mesoblast share price is resettling after a near-70% spike in December.

Read more »

Young investor watching share chart in anticipation
Healthcare Shares

Here's the earnings forecast out to 2029 for CSL shares

This biotech giant could see significant profit growth in the coming years.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »